Amanote Research
Register
Sign In
Synthesis of HCV Protease Inhibitor MK-6325
Synfacts
doi 10.1055/s-0034-1380762
Full Text
Open PDF
Abstract
Available in
full text
Date
May 18, 2015
Authors
Unknown
Publisher
Georg Thieme Verlag KG
Related search
Structural and Thermodynamic Effects of Macrocyclization in HCV NS3/4A Inhibitor MK-5172
The Effect of Hepatic Impairment on the Pharmacokinetics of Asunaprevir, an HCV NS3 Protease Inhibitor
Antiviral Therapy
Infectious Diseases
Pharmacology
Synthesis of MK-8248
Synfacts
HCV RNA Quantification With Different Assays: Implications for Protease Inhibitor-Based Response-Guided Therapy
Antiviral Therapy
Infectious Diseases
Pharmacology
Pharmacodynamic Analysis of a Serine Protease Inhibitor, MK-4519, Against Hepatitis C Virus Using a Novel in Vitro Pharmacodynamic System
Antimicrobial Agents and Chemotherapy
Infectious Diseases
Pharmacology
Baseline Prevalence and Emergence of Protease Inhibitor Resistance Mutations Following Treatment in Chronic HCV Genotype 1-Infected Individuals
Antiviral Therapy
Infectious Diseases
Pharmacology
Liver-To-Plasma Vaniprevir (MK-7009) Concentration Ratios in HCV-infected Patients
Antiviral Therapy
Infectious Diseases
Pharmacology
Protease Inhibitor in Passion Fruit.
Nippon Eiyo Shokuryo Gakkaishi
Metalloprotoporphyrin Inhibition of HCV NS3-4A Protease: Structure–Activity Relationships
Drug Design, Development and Therapy
Drug Discovery
Pharmacology
Pharmaceutical Science
